Repligen Bundle
Who Owns Repligen Corporation?
Repligen Corporation, a key player in the life sciences sector, has a history rooted in scientific innovation. Founded in 1981 by Professors Alexander Rich and Paul Schimmel, the company initially aimed to develop pharmaceutical therapeutics.
Today, Repligen is a vital supplier for biopharmaceutical manufacturing, with revenues reaching $634.4 million in 2024. Its products are crucial for producing advanced therapies, as detailed in the Repligen PESTEL Analysis.
Who Founded Repligen?
Repligen Corporation was co-founded in 1981 by two prominent scientists, Professor Alexander Rich and Professor Paul Schimmel. Both were affiliated with the Massachusetts Institute of Technology (MIT), with Professor Rich being a foundational figure in molecular biology. Their scientific vision guided the company's initial focus on developing pharmaceutical therapeutics.
| Founders | Professor Alexander Rich, Professor Paul Schimmel |
| Founding Year | 1981 |
| Initial Focus | Development of pharmaceutical therapeutics |
| Early Funding | Venture capital and collaborations |
Founding Scientists
Repligen was established by Professor Alexander Rich and Professor Paul Schimmel. Both were distinguished scientists with strong ties to MIT.
Scientific Vision
The founders' expertise in molecular biology and chemical biology shaped the company's early direction. Their aim was to innovate within the biopharmaceutical sector.
Early Business Model
As a startup in the biotechnology field during that era, Repligen likely relied on venture capital and strategic partnerships for initial funding.
Professor Rich's Role
Professor Alexander Rich served as a co-Chairman of Repligen's Board of Directors for a significant period, stepping down in 2014.
Professor Schimmel's Expertise
Professor Paul Schimmel contributed his extensive scientific knowledge, particularly in chemical biology, to the company's inception.
Founding Ownership Details
Specific details regarding initial equity splits or precise shareholdings at the company's founding are not publicly disclosed.
While precise equity splits at inception are not publicly detailed, the early funding for Repligen Corporation, founded in 1981, was typical for biotechnology startups of that period, relying on venture capital and collaborations. The foundational vision of co-founders Professor Alexander Rich and Professor Paul Schimmel was crucial in establishing the company's direction toward innovative solutions for the biopharmaceutical industry. Information regarding early ownership disputes, specific vesting schedules, or buy-sell clauses from this initial phase is not available in public records.
Key Aspects of Repligen's Founding
The early days of Repligen were characterized by the scientific acumen of its founders and a strategic focus on therapeutic development.
- Co-founded by MIT professors Alexander Rich and Paul Schimmel in 1981.
- Initial business focus was on pharmaceutical therapeutics.
- Early funding likely sourced from venture capital and industry collaborations.
- Professor Alexander Rich held a significant board role until 2014.
- The founders' scientific expertise was central to the company's inception.
- Detailed early ownership structures are not publicly available.
Repligen SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Repligen’s Ownership Changed Over Time?
Repligen's ownership structure has evolved significantly since its public debut in 1986. A key strategic pivot occurred around 2011-2012, when the company focused exclusively on its bioprocessing business after acquiring crucial Protein A ligand technology and divesting its Orphan Drug Portfolio. This strategic realignment has shaped its investor base and driven its subsequent growth.
| Shareholder Type | Percentage of Ownership (Approx.) | Key Holders |
|---|---|---|
| Institutional Investors | 64.39% - 85.59% | T. Rowe Price Group, Inc., BlackRock, Inc., Vanguard Group Inc, Point72 Asset Management, L.P., iShares, State Street Corp. |
| Insiders (Officers & Directors) | 0.64% - 0.78% | Executive officers and directors |
As of August 2025, institutional investors are the dominant force in Repligen's ownership, holding a substantial majority of the company's stock. This reflects its established presence in the bioprocessing sector. T. Rowe Price Group, Inc. held 12.7% as of June 2025, while BlackRock, Inc. and Vanguard Group Inc held 6.8 million and 5.1 million shares respectively as of March 2025. These large institutional holdings underscore the company's appeal to long-term investors focused on the bioprocessing industry. Strategic acquisitions, such as Tantti Laboratory Inc. in December 2024 for $74.8 million, further bolster Repligen's position and its Revenue Streams & Business Model of Repligen.
Key Stakeholders in Repligen
Institutional investors represent the largest segment of Repligen's ownership. These entities manage large portfolios and often take significant stakes in companies they believe have strong growth potential.
- T. Rowe Price Group, Inc. is a major institutional shareholder.
- BlackRock, Inc. holds a substantial number of shares.
- Vanguard Group Inc also maintains a significant investment.
- Other notable institutional investors include Point72 Asset Management, L.P., iShares, and State Street Corp.
- Insider ownership remains a small but important percentage of total shares.
Repligen PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Repligen’s Board?
The strategic direction and oversight of Repligen Corporation are currently guided by its Board of Directors, a body comprising both independent directors and key leadership figures. As of the 2025 Proxy Statement, the board's composition reflects a commitment to robust corporate governance.
| Board Member | Role | Key Committee Assignments |
| Olivier Loeillot | President and Chief Executive Officer | N/A |
| Tony J. Hunt | Executive Chair of the Board | N/A |
| Karen A. Dawes | Lead Independent Director | Audit Committee |
| Glenn P. Muir | Director | Audit Committee |
| Nicolas M. Barthelemy | Director | Compensation Committee |
| Martin D. Madaus | Director | Nominating & Corporate Governance Committee |
| Carrie Eglinton Manner | Director | Audit Committee, Compensation Committee |
| Rohin Mhatre | Director | Compensation Committee, Nominating & Corporate Governance Committee |
| Konstantin Konstantinov | Director | Audit Committee, Nominating & Corporate Governance Committee |
Repligen's voting structure operates on a standard one-share-one-vote principle, consistent with publicly traded entities on the NASDAQ exchange. This structure ensures that each share of common stock typically carries equal voting rights, without any indications of dual-class share arrangements or special voting privileges that could concentrate control. The company's governance has not recently been subject to significant disruptions from proxy battles or activist investor campaigns, suggesting a stable shareholder base and management alignment. Understanding the board's composition and the voting power structure is key to grasping Repligen ownership dynamics and the broader Repligen stock ownership landscape.
Understanding Repligen's Governance
Repligen's Board of Directors is instrumental in shaping its strategic path and ensuring effective corporate governance. The board includes a blend of executive leadership and independent directors, each contributing diverse expertise.
- Olivier Loeillot serves as President and CEO.
- Tony J. Hunt transitioned to Executive Chair of the Board.
- Karen A. Dawes leads as the Lead Independent Director.
- The board oversees key committees like Audit, Compensation, and Nominating & Corporate Governance.
- Repligen adheres to a one-share-one-vote principle for its stock.
Repligen Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Repligen’s Ownership Landscape?
Repligen Corporation has seen shifts in its leadership and strategic direction over the past few years, impacting its ownership trends. The company is publicly traded, meaning its stock is available for purchase by a wide range of investors, including individuals and institutions.
| Metric | 2023 | 2024 | Q1 2025 | Q2 2025 |
|---|---|---|---|---|
| Total Revenue | $632.4 million | $634.4 million | $169 million | $182 million |
| Net Income/(Loss) | $35.6 million | ($25.5 million) | N/A | N/A |
| Organic Non-COVID Growth | N/A | N/A | 14% | 15% |
In recent developments, Olivier Loeillot assumed the role of President and CEO in September 2024, taking over from Tony Hunt, who transitioned to Executive Chair. The company also made a strategic acquisition in December 2024, purchasing Tantti Laboratory Inc. for $74.8 million to bolster its presence in emerging modality areas. Repligen has also raised its full-year 2025 revenue guidance to a range of $715 million to $735 million. While specific large-scale share buybacks haven't been a recent focus, insider trading activity has been noted, with executives and directors participating in transactions during late 2024 and 2025. The shareholder base shows a strong trend towards increased institutional ownership, with these entities holding a significant majority of the company's stock, reflecting confidence in Repligen's Growth Strategy of Repligen. The company also released its 2024 Corporate Sustainability Report in May 2025, underscoring its dedication to sustainable operations.
Leadership Transition
Olivier Loeillot became President and CEO in September 2024. Tony Hunt moved to Executive Chair.
Strategic Acquisition
The company acquired Tantti Laboratory Inc. for $74.8 million in December 2024. This move aims to enhance its portfolio in new modality spaces.
Financial Outlook 2025
Full-year 2025 revenue guidance has been increased to $715 million - $735 million. Q1 2025 revenue reached $169 million, with Q2 2025 revenue at $182 million.
Ownership Trends
Institutional investors hold a substantial majority of Repligen's stock. Insider trading activity has been reported in late 2024 and 2025.
Repligen Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Repligen Company?
- What is Competitive Landscape of Repligen Company?
- What is Growth Strategy and Future Prospects of Repligen Company?
- How Does Repligen Company Work?
- What is Sales and Marketing Strategy of Repligen Company?
- What are Mission Vision & Core Values of Repligen Company?
- What is Customer Demographics and Target Market of Repligen Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.